Laurus Labs is currently trading at Rs. 457.90, up by 8.55 points or 1.90% from its previous closing of Rs. 449.35 on the BSE.
The scrip opened at Rs. 453.50 and has touched a high and low of Rs. 459.75 and Rs. 450.00 respectively. So far 32636 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 626.00 on 19-Apr-2022 and a 52 week low of Rs. 433.20 on 28-Jan-2022.
Last one week high and low of the scrip stood at Rs. 461.95 and Rs. 444.40 respectively. The current market cap of the company is Rs. 24616.43 crore.
The promoters holding in the company stood at 27.27%, while Institutions and Non-Institutions held 31.99% and 40.74% respectively.
Laurus Labs, as per the policy of the Government for captive consumption of power, has entered into Share Subscription agreement and Shareholders’ agreement on November 23, 2022 with Ethan Energy India for subscribing 7,40,000 Equity Shares of face value of Rs 10 each at a premium of Rs 42.70 which is equivalent to 26% of the paid up capital of Ethan Energy India. This will enable the Company to consume 100% of the solar energy to be supplied by Ethan Energy India from their 10 MW Solar Energy plant.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1861.70 |
Dr. Reddys Lab | 1389.35 |
Cipla | 1506.15 |
Lupin | 2228.00 |
Zydus Lifesciences | 972.70 |
View more.. |